Steffen Ormanns

leaving Twitter soon. follow me on bluesky: @stf-orm.bsky.social

[Pancreatobiliary Pathology Society @pbpath]

Mark your calendars! Enhance your skills with PBPS & #USCAP’s interactive course on pancreatobiliary pathology. Details below-

https://t.co/ZqQCNLdi9V

@MichelleReidMD @OlcaBasturk @Huaminwang6
@AgostiniVulajDO @Mvgs1706 @CLuchini10
@navale_pooja @VidyaArole @DrVish

[European Society of Pathology (ESP) @ESP_Pathology]

🧪🥼A #pathology department requires a team of well-trained professionals to operate effectively!

🔬🧬It is thus a great pleasure to announce that for the first time the #ESPCongress will include a 1-day symposium dedicated to technicians!

Info: https://t.co/MPM19l1C1i

[Gabriele Capurso MD, PhD🇺🇦 @lelecapurso]

who knows who they are referring to....

[Joan Lop Gros @JoanWolfBig1]

Finally! our comprehensive review on Claudin 18.2 IHC expression in gastric cancer has been published in Applied Immunohistochemistry & Molecular Morphology! Check it out now! #CancerResearch #GastricCancer #Claudin18.2 #IHC #AIM

[Ben Westphalen @BenWestphalen]

1/2 Matching #patients to #clinicaltrials is one of the most important tasks of a molecular tumour board. #OpenAccess in @Nature_NPJ #PrecisionOncology evaluates four clinical trial matching tools in this setting.

#PrecisionMedicine @OncoAlert 🚨
https://t.co/meBe8aPGtV

[OncoAlert @OncoAlert]

Dear Colleagues
The OncoAlert🚨 Network along with our partners at
@ESSOnews @ESGO_society @CancerCareMASCC & @SIOGorg invite you to the #OncoAlertColloquium

REGISTER for FREE HERE👉 https://t.co/PxzkNquScn
February 3-9, 2025 💯% Virtual & Interactive

Watch Our #GI Faculty
@BenWestphalen of CCC Munich LMU

Presenting on #PancreaticCancer year in Review on February 6, 2025

Our Collaborators
APCCC, ABC Global , GUARD Consortium , @mybsmo, GU Cast, KidneyCan

Huge thanks to our friend
@ONCOassist and @OncobitesTv

@pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
@heinrich_kat @Dr_Ivanoncologo

#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK

[Nicholas Hornstein @GIMedOnc]

#GI25
Is it the hardest to pronounce name of any antibody? Yes.

It is also probably the best new treatment for GI malignancies? Also, probably yes.

Daraxonrasib, pan-KRASi
Amazing responses in second line PDAC
Making the undruggable druggable.

(Someone please teach me how to pronounce this.)

[Steffen Ormanns @Orm_Stf]

I will shortly leave X for the same reasons as everybody else who is leaving. Please follow me on bluesky!
@stf-orm.bsky.social

[Steffen Ormanns @Orm_Stf]

@emma_furth Close to zero? Well... I would say this will rarely be diagnostic for AIP.

[Shiv K Singh & Lab @ShivKSingh6]

📢 Excited to share our study in @NatureComms, previously available on bioRxiv by Klein et al.
👉 https://t.co/tqT4g9d39B

[Steffen Ormanns @Orm_Stf]

@CancerCytopath @duckhuca Careful with this marker though... In the right setting very useful esp. in combination with GATA3. However keep in mind that its expression isn't limited to BrCa. In fact, many carcinomas may be positive at least in some extent. #PathTwitter

[Steffen Ormanns @Orm_Stf]

https://t.co/UhUxjOpByu

Check our review on XPO1 function in cancer. Thanks for the great collaboration! @tirol_kliniken @MedUniInnsbruck

[Dr Joseph McCollom DO @realbowtiedoc]

Compact #GIonc review article in
@JCOOP_ASCO

@VictoriaLChung and colleagues explore 🎯 in #pancsm

⭐️KRAS WT 10%
⭐️NRG-zenocutuzumab
⭐️BRAF V600E-BRAF/MEK inh
⭐️NTRK-larotrectinib
⭐️HER2 ⭐️BRCA⭐️PALB2,
⭐️Claudin high potential
#IO limited, except in #MSI-H cases.

🔗: https://t.co/J89IAiNL4A

@OncoAlert🚨
@TimothyJBrownMD
#OncoAlertAF
@yekeduz_emre
@FadiHaddad_MD
@Abdallah81MD
@Erman_Akkus
@Abdallah81MD
@bavilima
@acampsmalea
@DrFMartinelli
@lungoncdoc
@Dr_Ivanoncologo
@orellanauro
@FernandoOnco
@Lucarecco
@HHorinouchi
@ElisaAgostinett
@to_be_elizabeth
@BiagioRicciutMD
@nataliagandur
@weoncologists
@OncoReporte

[Steffen Ormanns @Orm_Stf]

@Aiims1742 Very similar work from 2023 from a french collaborative effort. Stromal and tumor subtypes based on PurIST in large multicentric test and validation cohorts: https://t.co/bQoCxNkpxP

[DJ P.R. 🙄 @djpr]

🤷

[Steffen Ormanns @Orm_Stf]

@dokhollidays Hab in Grenoble famuliert... Grobes Gesöff... 😜

[Steffen Ormanns @Orm_Stf]

@MPishvaian @EileenMOReilly @visheshkhanna @glovedoc @PanCAN @lustgartenfdn @letswinpc @benweinbergmd @CentralParkWMD @DrShubhamPant @carisls @FoundationATCG @TempusAI @tirol_kliniken We always test BRCA1/2 and PALB2 and more than often we do an upfront 165 gene panel. Depends a bit on how my molecular pathology department feels like... 😉

[Steffen Ormanns @Orm_Stf]

@MPishvaian @EileenMOReilly @visheshkhanna @glovedoc @PanCAN @lustgartenfdn @letswinpc @benweinbergmd @CentralParkWMD @DrShubhamPant @carisls @FoundationATCG @TempusAI That's why it makes sense to do at least MMR protein and panNTRK IHC in all PDACs and a more comprehensive molecular workup in KRASwt tumors. Our standard approach here @tirol_kliniken

[Steffen Ormanns @Orm_Stf]

@YehlabUNC @tirol_kliniken @CD_AACR